A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
Recruiting now
Conditions studied: Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional
In brief
In patients with epidermolysis bullosa (EB), collagen does not form properly, so their skin is very fragile and blisters easily. Such patients are also at greatly increased risk of developing skin cancers. Filsuvez is a topical gel used to promote healing of skin lesions in patients with certain types of EB. In this observational study, patients with either dystrophic EB (DEB) or junctional EB (JEB) will receive standard of care treatment, whether Filsuvez or something else, and will be followed for up to 5 years. The main purpose is to see if the use of Filsuvez affects the likelihood of developing skin malignancies in these patient populations.
Key facts
- Study ID
- NCT06423573
- Run by
- Amryt Pharma
- People needed
- 580
- Starts
- 2024-12-18
- Expected to finish
- 2032-08-01
- Last updated by the study team
- 2025-09-19
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with a confirmed diagnosis of dystrophic EB or junctional EB
You may not qualify if…
- None
Where it is running
- CHU de Toulouse, Hôpital Larrey — Toulouse, France (enrolling)
- Hospital of Skin and Venereal Diseases of Thessaloniki — Thessaloniki, Greece (enrolling)
- Hospital Clinic, Barcelona — Barcelona, Spain (enrolling)
- Hospital San Juan de Dios (Barcelona) — Barcelona, Spain (enrolling)
- Guy's and St Thomas' NHS Foundation Trust — London, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.